Bladder Cancer

Low Grade NMIBC (Non-Muscle Invasive Bladder Cancer)

TC-BC-12: The Efficacy and Safety of UGN-102 as a Primary Chemoablative Therapy in Patients With LG NMIBC at Intermediate Risk of Recurrence

Phase: 2
Study Product: UGN-102
Estimated Study Completion Date: September 2020
ClinicalTrials.gov Identifier: NCT03558503

Intermediate/High Risk NMIBC (HR NMIBC) Requiring Induction or Maintenance BCG

YHGT-NB-01: Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment

Phase: 1b/2
Study Product: APL-1202
Estimated Study Completion Date: October 2019
ClinicalTrials.gov Identifier: NCT03672240

HR NMIBC Post BCG

KEYNOTE-676: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in HR NMIBC

Phase: 3
Study Product: Pembrolizumab with BCG
Estimated Study Completion Date: November 25, 2024
ClinicalTrials.gov Identifier: NCT03711032

KEYNOTE-057: Study of Pembrolizumab (MK-3475) in Participants With HR NMIBC

Phase: 2
Study Product: Pembrolizumab
Estimated Study Completion Date: July 30, 2023
ClinicalTrials.gov Identifier: NCT02625961

CheckMate 9UT: A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without BCG in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Phase: 2
Study Product: Nivolumab vs. Nivolumab with BCG vs. Nivolumab with BMS-986205 vs. Nivolumab with BMS-986205 with BCG
Estimated Study Completion Date: April 16, 2023
ClinicalTrials.gov Identifier: NCT03519256

Advanced/Metastatic Urothelial Carcinoma (UC)

FIGHT-201: A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma

Phase: 2
Study Product: Pemigatinib
Estimated Study Completion Date: January 2020
ClinicalTrials.gov Identifier: NCT02872714